Table 1.
Characteristics of cohort patients at cohort entry.
| Demographics & comorbilities | Total (n = 544) | Tocilizumab |
Control (n = 347) | p Value* | ||
|---|---|---|---|---|---|---|
| All (n = 197) | Early (n = 147) | |||||
| Age (years; ± SD) | 62.1 ± 13.8 | 61.0 ± 13.5 | 60.0 ± 13.5 | 62.7 ± 13.9 | 0.18 | 0.05 |
| Male sex | 341 (62.7) | 132 (67.0) | 95 (64.6) | 209 (60.2) | 0.12 | 0.36 |
| Obesity | 197 (36.2) | 88 (44.7) | 66 (44.9) | 109 (31.4) | 0.002 | <0.01 |
| Asthma/COPD | 91 (16.7) | 38 (19.3) | 26 (17.7) | 53 (15.3) | 0.23 | 0.50 |
| Cancer/Haematology malignancy | 57 (10.5) | 19 (9.6) | 12 (8.2) | 38 (11.0) | 0.63 | 0.35 |
| Hypertension | 239 (43.9) | 84 (42.6) | 63 (42.9) | 155 (44.7) | 0.65 | 0.71 |
| Diabetes | 137 (25.2) | 43 (21.8) | 30 (20.4) | 94 (27.1) | 0.18 | 0.12 |
| Transplantation/VIH | 28 (5.2) | 17 (8.6) | 8 (5.4) | 11 (3.2) | 0.006 | 0.23 |
| Chronic renal disease | 42 (7.7) | 20 (10.2) | 11 (7.5) | 22 (6.3) | 0.11 | 0.64 |
| SpO2/FiO2 ratio (±SD) | 256.1 ± 100.2 | 209.6 ± 94.5 | 206.3 ± 94.5 | 282.5 ± 93.7 | <0.001 | <0.001 |
| Interleukin-6 μL/L (±SD) | 166.6 ± 644.1 (n = 509) | 151.2 ± 282.7 (n = 187) | 160.3 ± 258.0 (n = 145) | 175.5 ± 781.1 (n = 322) | 0.68 | 0.82 |
| D-dimer mcg/Ml (±SD) | 491.0 ± 1575.2 (n = 369) | 439.0 ± 508.4 (n = 138) | 436.8 ± 444.5 (n = 103) | 522.5 ± 1952.7 (n = 231) | 0.62 | 0.66 |
Data are presented as n (%) unless otherwise noted. SD: standard deviation
*
p Value obtained comparing Tocilizumab group (all/early) with Control group.